MedTrace Logo

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

NCT00335660 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2008-02-25

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Idiopathic Detrusor Overactivity.

Conditions

  • Overactive Bladder Syndrome

Interventions

DRUG

AV608

Sponsors & Collaborators

  • Avera Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Linda Cardozo, MD FRCOG · King's College Hospital NHS Trust

  • Joao Siffert, MD · Avera Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-06-30
Completion
2007-09-30

Countries

  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00335660 on ClinicalTrials.gov